A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

Gamez, Josep; Calopa, Matilde; Muñoz, Esteban; Ferré, Aileen; Huertas, Oscar; McAllister, Kevin; Reig, Núria; Scart‐Grès, Catherine; Insa, Raúl; Kulisevsky, Jaime

doi:10.1111/bcp.15635

Public

A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

Shared by NobleBlocks on Dec 28, 2022 • 12:00 AM UTC

Authors:

Josep Gamez

Matilde Calopa

Esteban Muñoz

Abstract

Aims The study's aim is to investigate the efficacy and safety of SOM3355 (bevantolol hydrochloride), a β 1 ‐adrenoreceptor antagonist with recently identified vesicular monoamine transporter type 2 inhibitory properties, as a repositioned treatment to reduce chorea in Huntington's disease (HD). Met...

Discussions